A study suggests a 16-protein blood test, the Sjögren’s protein score, may measure salivary gland inflammation without biopsy. The score correlated with glandular inflammation, antibodies, and extraglandular disease features.
A study published in The Journal of Clinical Investigation found that CXCL11 may help drive endocrine resistance in some hormone receptor-positive breast cancers. Researchers said ED-resistant tumors had increased immune signaling and may be more responsive to immunotherapies.
Cardinal Health has recalled certain lots of Webcol Large Alcohol Prep Pads due to potential contamination with Paenibacillus phoenicis bacteria. The affected pads were distributed between September 2025 and February 2026 and pose infection risks, particularly for immunocompromised individuals. The FDA is aware of the voluntary recall.
A study of 366 patients found ide-cel CAR-T cell therapy achieved 81.6% overall response rate in patients 70 or older with relapsed/refractory multiple myeloma, with median progression-free survival of 18.9 months versus 5.7 months with standard regimens.
Research communities in the US and UK face funding disruptions as governments demand greater alignment with national priorities. UKRI has paused grant programs while early-career researchers advocate for increased NIH funding.
CAR T-cell therapy is delivering unprecedented results for multiple myeloma patients, with CARTITUDE-1 trial data showing one-third of patients remaining progression-free for five years or more, raising the possibility of cure for some patients.
New studies show SGLT2 inhibitors and GLP-1 receptor agonists reduce risks of kidney failure, cardiovascular events, and liver complications in patients with type 2 diabetes, with particularly strong benefits in those with cirrhosis.
AstraZeneca's CALQUENCE received FDA approval as the first all-oral, fixed-duration regimen for chronic lymphocytic leukemia, while the EMA validated the marketing authorization application for ENHERTU in HER2-positive breast cancer treatment.
CAR T-cell therapy is delivering high remission rates for multiple myeloma patients, with improved handoff communication reducing infection risks. FDA-approved BCMA-targeting products show response rates from 72% to 98% in heavily pretreated patients.
The FDA approved the combination of acalabrutinib and venetoclax as the first all-oral, fixed-duration regimen for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma, based on Phase 3 AMPLIFY trial results.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07598006 |
Hypervirulent Amoxicillin-Susceptible Klebsiella Pneumoniae CC66, France, 2016-2023 |
COMPLETED | |
| NCT07512141 |
Single Versus Double Drains in the Axillary and Pectoral Regions After Modified Radical Mastectomy |
RECRUITING | NA |
| NCT07487506 |
Evaluation and Assessment for Communicable Diseases in Migrants Hosted in Reception Centers |
RECRUITING | NA |
| NCT07379554 |
Personalized Immunological Score for the Prediction of Severe Infectious Events in Immunocompromised Patients and Tailored Management (PERISCOPE) |
RECRUITING | |
| NCT07347301 |
Head-Only Draping in Pediatric Tonsillectomy |
NOT_YET_RECRUITING | NA |
| NCT07342972 |
Gastrointestinal Symptoms and Tolerance in Infants Fed Goat or Cow's Milk-based Infant Formula |
NOT_YET_RECRUITING | NA |
| NCT07329114 |
Healing Electroceutical Dressing for the Recovery of Open Wounds (HERO) |
RECRUITING | NA |
| NCT07315568 |
Couples and Microbial Diversity |
NOT_YET_RECRUITING | |
| NCT07220915 |
Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections |
NOT_YET_RECRUITING | PHASE3 |
| NCT07215871 |
Rechallenge With a Low Pathogenicity Avian H10N7 Influenza Virus in Healthy Human Volunteers Previously Challenged With H10N7 Influenza |
ENROLLING_BY_INVITATION | PHASE1 |
